United States · Compounding pharmacy · Compounded

VIOS Compounding Pharmacy review

A prescriber-only compounding pharmacy that, unlike Empower, does not state whether it operates as 503A or 503B.

Reviewed 2026-08-157/13 checklist items publishedProvider site ↗

Overview

VIOS compounds tirzepatide injections “prepared by a compounding pharmacy according to a licensed healthcare provider’s directions,” dispensed on prescription only. Like Empower it is supply-side rather than a route in — patients must work through their own provider.

The instructive contrast is with Empower. Empower states its 503A designation, publishes exact vial concentrations, and carries an explicit FDA disclosure on the product page. VIOS states none of the three: no 503A or 503B designation, no concentrations, no FDA statement, and no pricing.

What it does emphasise is clinical oversight — the product is repeatedly described as “provider-guided,” and it states “patients should speak with their provider about potential risks, side effects, dosing expectations.” That is sound advice, but it is not the same as disclosing what is in the vial.

Medications and supply

Compounded. The 503A or 503B designation is not stated, and no FDA disclosure appears on the page.

  • Compounded tirzepatide injection

How the service works

Consultation
None. A prescription from your own licensed healthcare provider is required.
Eligibility
A valid prescription is required.
Provider involvement
None directly. VIOS describes the product as provider-guided and directs questions to the prescriber.
Lab requirements
Not stated in the sources we checked.
Pharmacy fulfilment
Its own compounding facility; regulatory designation not stated.
Shipping
Not stated in the sources we checked.
Support services
Not stated in the sources we checked.

What it costs

Published prices for VIOS Compounding Pharmacy
ItemPublished priceNotes
Compounded tirzepatide injectionnot published
Membership fee
None — there is no subscription.
Medication fee
Not published.
Insurance
Not stated in the sources we checked.
HSA / FSA
Not stated in the sources we checked.
Cancellation
Not applicable.
Refunds
Not stated in the sources we checked.

Pros

  • Prescription-only, so it is not selling directly to patients
  • Emphasises that dosing questions belong with your prescriber

Cons

  • Does not state whether it is a 503A or 503B facility
  • No vial concentrations published
  • No FDA disclosure on the product page
  • No pricing published

Who it may suit

A prescriber choosing a compounder — who should ask for the regulatory designation and concentrations that this page does not provide.

Limitations

  • Compounded products are not FDA-approved
  • Materially less disclosure than Empower Pharmacy offers for a comparable product

Questions

Is VIOS a 503A or 503B pharmacy?

The page does not say. That matters — a 503A compounds against an individual patient-specific prescription while a 503B outsourcing facility can produce in bulk. Empower Pharmacy states its designation; VIOS does not.

Can I order directly?

No. A prescription from your own licensed healthcare provider is required.

Sources

Everything on this page traces to one of the links below, retrieved on the date shown. Prices and programme terms in this market change without notice — confirm against the provider before you buy.

  1. 01VIOS Compounding — tirzepatide injections, prescription requirement, provider-guided framingretrieved 2026-08-15